Recent research on pharmacological prevention strategies for invasive fungal infection in preterm infants.
10.7499/j.issn.1008-8830.2204158
- Author:
Fang-Jun HUANG
1
;
Tao XIONG
1
;
Jun TANG
1
Author Information
1. Department of Pediatrics, West China Second Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Extremely low birth weight infant;
Fluconazole;
Invasive fungal infection;
Preterm infant;
Prophylaxis;
Very low birth weight infant
- MeSH:
Infant, Newborn;
Humans;
Infant, Premature;
Infant, Very Low Birth Weight;
Infant, Premature, Diseases/prevention & control*;
Antifungal Agents/therapeutic use*;
Intensive Care Units, Neonatal;
Invasive Fungal Infections/prevention & control*
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(10):1171-1177
- CountryChina
- Language:Chinese
-
Abstract:
There is a relatively high incidence rate of invasive fungal infection (IFI) in preterm infants admitted to the neonatal intensive care unit (NICU), and early diagnosis of IFI is difficult in clinical practice. The patients developing IFI tend to have severe conditions, a long course of treatment, high hospital costs, high mortality, and poor prognosis, and therefore, the prevention of IFI is of particular importance. At present, fluconazole is often used as the first-line drug for the prevention of IFI in preterm infants, but no consensus has been reached on the specific dose and course of treatment, and there are still controversies over the targeted population and prophylactic effect. This article reviews the recent research on the pharmacological prevention strategies for IFI in preterm infants in the NICU, so as to provide a reference for clinicians.
